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Stressful life events during childhood and adolescence are important risk factors for the development of
psychopathologies later in life. The corticotropin releasing hormone (CRH) and the CRH receptor 1
(CRHR1) have been implicated in the link between early life adversity and adult anxiety and depression,
with rodent studies identifying the very early postnatal period as highly susceptible to this programming.
Here, we investigated whether stress exposure during the peripubertal period e comprising juvenility
and puberty e is effective in inducing long-lasting changes in the expression of CRHR1 and CRHR2 in the
hippocampus and amygdala, and whether treating animals with a CRHR1 antagonist following stress
exposure could reverse behavioral alterations induced by peripuberty stress. We show that peripuberty
stress leads to enhanced expression of the Crhr1, but not Crhr2, gene in the hippocampal CA1 and the
central nucleus of the amygdala, in association with social deﬁcits in the social exploration test and
increased stress-coping behaviors in the forced swim test. Treatment with the CRHR1 antagonist
NBI30775 (10 mg/kg) daily for 1 week (from P43 to P49), immediately following peripuberty stress
exposure, prevented the occurrence of those psychopathological behaviors at adulthood. These ﬁndings
highlight peripuberty as a period of plasticity for the enduring modulation of the CRHR1 system and
support a growing body of data implicating the CRHR1 system in the programming effects of early life
stress on eventual psychopathology. They also support recent evidence indicating that temporarily
tackling CRHR1 during development might represent a therapeutic opportunity to correct behavioral
trajectories linking early stress to adult psychopathology.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Corticotropin releasing hormone (CRH) is critically implicated in
the regulation of the physiological stress response and in the
development of stress-related psychopathological behaviors
(Steckler and Holsboer, 1999; Risbrough and Stein, 2006; Holsboer
and Ising, 2008; Mathew et al., 2008; Binder and Nemeroff, 2010)
including those induced by early adversity (Coplan et al., 1996;
Nemeroff, 2004; Heim et al., 2008). The CRH family comprises
several ligands (CRH and urocortins 1, 2 and 3) and two receptors,
CRH receptor 1 (CRHR1, to which CRH and urocortin 1 bind pref-
erentially) and the CRH receptor 2 (CRHR2), both present in the
hypothalamus as well as in limbic brain areas including the
amygdala and hippocampus (Binder and Nemeroff, 2010). In addi-
tion to its key role in modulating peripheral responses through the
activation of the hypothalamusepituitaryeadrenal (HPA) axis, theCRH/CRHR1 system plays a critical role in mediating some types of
anxiety and depression responses (Dunn and Berridge, 1990;
Contarino et al., 1999; Steckler and Holsboer, 1999; Muller et al.,
2003; Muller and Wurst, 2004; Todorovic et al., 2005; Ivy et al.,
2010; Wang et al., 2012). Application of CRHR1 antagonists exerts
anxiolytic and antidepressant-like effects in animals with high
levels of anxiety and in animals that have been pre-exposed to
stressors (Keck et al., 2001; Lancel et al., 2002; Sandi et al., 2008).
In rodents, early life stress e induced during the very early
postnatal period by either maternal separation or unstable
maternal care e was found to lead to increased anxiety-like be-
haviors and cognitive deﬁcits in association with increased central
CRH and CRHR1 expression (Plotsky et al., 2005; Fenoglio et al.,
2006; Ivy et al., 2010; Wang et al., 2011, 2012). Manipulation of
the CRHR1 system during development during the aftermath of
early life stress exposure was found to prevent some of the long-
term behavioral alterations observed at adulthood. Thus, in a
model of unstable maternal care, either the administration of a
CRHR1 antagonist in the developmental period following the
maternal stress manipulation (Ivy et al., 2010) or a conditional
Fig. 1. Layout of the general experimental design: stressors were applied during the
peripuberty period in both experiments 1 and 2. In experiment 1 (shown in upper
panel), at adulthood (P90þ), animals were sacriﬁced under basal condition and the
brains were later utilized for gene expression study. In experiment 2 (shown in the
lower panel), animals (both control and peripubertal stress) were injected (i.p.; vehicle
or NBI30775) from P43 to P49. In adulthood (P90þ), batteries of behavioral tests were
performed in the order shown in the schematic.
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has elapsed (Wang et al., 2011, 2012) were found to prevent the
emergence of anxiogenic effects and cognitive impairments
induced by unstable maternal care. These ﬁndings suggest that
early interventions tackling the CRHR1 system following exposure
to early life stress might be an effective approach to prevent the
incidence of psychopathologies in later life. However, so far, these
studies have involved very early stress manipulations occurring
within the ﬁrst two weeks of postnatal life and there is no infor-
mation regarding the involvement of the CRHR1 system and the
potential therapeutic value of CRHR1-targeted treatments when
stress exposure takes place slightly later in development.
In fact, stress during childhood and puberty e termed hereafter
as the peripubertal period e has been associated with psychopa-
thology later in life (Heim and Nemeroff, 2001; Watt et al., 2009).
The peripubertal period is a biological transitional phase involving
adaptations in hormonal systems and neural circuits, including
those related to stress and the development of emotionality (Spear,
2009; Romeo, 2010). In our lab, exposure of rats to stressful expe-
riences (e.g., synthetic fox odor and exposure to an elevated plat-
form) on scattered days during the peripuberty period (P28eP30,
P34, P36, P40 and P42) was found to induce long-lasting effects on
anxiety and stress-coping behaviors, including deﬁcits in social
behaviors (Toledo-Rodriguez and Sandi, 2011; Cordero et al., 2012;
Marquez et al., 2013), as well as changes in metabolic responses in
limbic brain regions including the hippocampus and the amygdala
(Toledo-Rodriguez et al., 2012; Marquez et al., 2013). Here, we
sought to investigate whether peripuberty stress would lead to
alterations in the CRH system in limbic areas and whether phar-
macological treatment with a CRHR1 antagonist during the im-
mediate post-stress developmental period (i.e., adolescence) would
reverse the long-term behavioral consequences of peripuberty
stress.
2. Materials and methods
2.1. Animals
The study was conducted on male offspring of Wistar Han rats
purchased from Charles River Laboratories, France, and bred in our
animal house. After weaning at postnatal day P21, male rats from
different litters were mixed throughout the different home cages
(three per cage). Equivalent numbers of animals from each litter
were placed in four groups (see below) and the placement of sib-
lings within the same home cage was avoided. All animals were
kept in constant conditions of humidity and temperature
(221 C)with a 12-h lightedark cycle (lights on at 7:00 AM). Food
and water were available ad libitum. All the procedures described
were conducted in conformity with Swiss National Institutional
Guidelines on Animal Experimentation and approved through a
license granted by the Swiss Cantonal Veterinary Ofﬁce Committee
for Animal Experimentation.
2.2. Experimental design
Two experiments were performed (see experimental design in
Fig. 1). The ﬁrst one was conducted to evaluate the long-term
consequences of peripuberty stress in the expression levels of
CRHR1 and CRHR2 in the hippocampus and amygdala at adulthood.
At adulthood, control and peripuberty stressed animals were
decapitated under basal conditions. After decapitation, the brains
were fast frozen in isopentane and then stored at 80 C. The
dissection of the different hippocampal subregions [dentate gyrus
(DG), CA1 and CA3] and amygdala nuclei [central amygdala (CeA)
and basolateral amygdale (BLA)] for gene expression analyses wasperformed by tissue punching in 200 mm slices sectioned on
cryostat.
The second experiment was performed to investigate the po-
tential efﬁcacy of treatment with the CRHR1 antagonist, NBI30775,
during adolescence to counteract long-term behavioral alterations
induced by peripuberty stress. We followed a 2 2 experimental
design, with Stress and Drug as factors, which led to the following
four groups: (1) Control-Vehicle, (2) Control-NBI30775, (3) Stress-
Vehicle, and (4) Stress-NBI30775. Drug treatment was given
intraperitoneally (i.p.) and daily from postnatal day P43 to P49. At
adulthood, all animals were tested for anxiety-like and stress-
coping behaviors, which included the elevated plus maze task;
the social preference test, and the forced swim test. A residente
intruder test was also included but due to the corruption of a large
number of video recordings of the encounters, data from the resi-
denteintruder task are not included here. The minimum time
elapsed between tests was 1 week.
2.3. Peripuberty stress paradigm
This protocol is based on exposure to fear-induction procedures
(Marquez et al., 2013). Following exposure to an open ﬁeld for
5 min on P28, the stress protocol consisted of presenting two
different fear-inducing stressors (each one lasting 25 min): (1)
exposure to the synthetic fox odor trimethylthiazoline (9 ml) (Phero
Tech Inc., Delta, BC, Canada) released through a small cloth, in a
plastic box (38 cm length, 27.5 cm width and 31 cm height) placed
under a bright light (210e250 lx); and (2) exposure to an elevated
platform (12  12 cm, elevated 95 cm from the ground) under
direct bright light (470e500 lx). Following each stress session, the
animals were returned to their home cages where, for 15 min, a
transparent Plexiglas wall with holes separated each animal. The
stressors were applied during the peripubertal period (a total of 7
days across postnatal day P28 to P42, i.e., on P28eP30, P34, P36,
P40 and P42); during the light phase; and according to a variable
schedule. The order and timing of the stressors were changed on
different days. On some stress days, only one stressor was pre-
sented, while on other days, the two stressors were given consec-
utively. The control animals were handled on the days that their
experimental counterparts were exposed to stress.
2.4. CRHR1 and CRHR2 mRNA analyses
Total RNA was isolated using the RNAqueous Micro kit
(Ambion) and cDNAwas synthesized using the Superscript VILO kit
(Life Technologies) according to the supplier’s recommendations.
For quantitative PCR, PCR reactions were performed in triplicate
Fig. 2. Impact of peripubertal stress on Crhr1 gene expression in various hippocampal
areas [CA1 (A), CA3 (B) and DG (C)] and amygdala nuclei [BLA (D) and CeA (E)]. The
relative mRNA quantity of Crhr1 was signiﬁcantly different between control and PPS in
CA1 (A) and CeA (E). *p < 0.05. PPS, peripubertal stress. N ¼ 6e9/group.
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Prism 7900 Sequence Detection system (Applied Biosystems). Two
genes were used as internal controls: gamma-actin (actg1) and
eukaryotic elongation factor-1 (eef1). Crhr1 and Crhr2 primers were
designed using the Assay Design Center software from Roche
Applied Science. The primer sequences are provided in Table S1.
Gene expression was analyzed with qBase 1.3.5 software using the
comparative cycle threshold method (Livak and Schmittgen, 2001).
2.5. Drug administration
The CRHR1 antagonist NBI30775 was a gift from Neurocrine Inc.
It was administered intraperitoneally (i.p.) at 10 mg/kg in 4% v/v
dimethyl-sulfoxide/0.5% w/v methocellulose (Sandi et al., 2008)
daily from P43 to P49. The corresponding vehicle treatment was
administered to control animals on the same days and times.
2.6. Elevated plus maze
Anxiety levels were evaluated using the elevated plus maze
(EPM) test (Pellow and File, 1986). Brieﬂy, the test consists of two
opposing open arms (50  10 cm) perpendicular to two enclosed
arms (50  10  50 cm) that extend from a central platform
(10  10 cm), elevated 65 cm above the ﬂoor. The rats were placed
individually on the central platform facing a closed arm and
allowed to explore the maze for 5 min. Their behavior was moni-
tored using a video camera and analyzed with a computerized
tracking system (Ethovision 3.1.16, Noldus IT, The Netherlands). The
percent time spent and the number (frequency) of entries in the
center, open and closed arms were recorded. The entire apparatus
was cleaned (with 1% acetic acid solution) and dried between each
test.
2.7. Sociability test
The sociability test was adapted from the protocol described by
Crawley and collaborators to investigate social afﬁliation in male
mice (Moy et al., 2004). The test was carried out in a rectangular,
three-chambered gray opaque polycarbonate box (a center
20  35 35 cm; a left and a right compartment 30  35 35 cm).
Dividing walls had retractable doorways allowing access to each
chamber. Left and right compartments contained a central Plexiglas
cylinder (15 cm diameter), transparent and with small holes, where
either a social (unfamiliar juvenile rat around 34 days old) or a non-
social stimulus (yellow plastic bottle) was placed. The cylinder
permits visual, tactile, auditory and olfactory communication. The
juvenile rats used as social stimuli were ﬁrst habituated to the
three-chambered apparatus by placing them individually in the box
within the Plexiglas cylinder for 10 min during the 3 consecutive
days preceding the social test.
On testing day, the experimental rat was ﬁrst placed in the
middle chamber and allowed to explore for 5 min. The doorways
into the two side chambers were closed during this habituation
phase. After the habituation period, the unfamiliar juvenile was
placed in one of the side chambers and the object on the other side.
The location of the juvenile and the object in the left vs. right side
chamber was counterbalanced. Next, both doors to the side
chambers were carefully removed and the subject rat was allowed
to explore the entire apparatus for a 10 min session. The session
was video-recorded and the time spent snifﬁng each cylinder was
manually scored by an experimenter blind to treatments to eval-
uate the level of preference for the unfamiliar juvenile compared to
the object. A rat’s exploration of object or juvenile conspeciﬁc
(snifﬁng behavior) was deﬁned by nose proximity to the cylinders
at a distance less than 2 cm with the nose oriented toward thecylinders’ contents (i.e. juvenile or object) as detected by a
computerized tracking system (Ethovision 3.1.16, Noldus IT, The
Netherlands) and conﬁrmed with a computer software (Clicker,
EPFL, Switzerland) by an experimenter unaware of animals’ treat-
ments. The entire apparatus was cleaned (with 1% acetic acid so-
lution) and dried between each test.
2.8. Forced swim test
Rats were subjected to a forced swim test to evaluate stress-
coping behavior (Porsolt et al., 1977) following the same condi-
tions as in our previous study (Marquez et al., 2013). Brieﬂy, ani-
mals were individually placed in a plastic beaker (25 cm diameter,
46 cm deep) containing 30 cm of water (25 C) in two sessions. The
ﬁrst one lasted 15 min and the second one, performed 24 h later,
lasted 5 min. Behavior was recorded with a video camera and the
time spent ﬂoating (i.e., immobile with only those movements
necessary to keep the snout above water) was quantiﬁed by an
experimenter unaware of animals’ treatments using a computer
software (Clicker, EPFL, Switzerland).
2.9. Statistics
The SPSS 14.0 (SPSS, Chicago, IL) statistical package was used for
statistical analyses. Results are expressed as the mean  standard
error of the mean. Data of animals with mean value beyond 3
standard deviations (SDs) from its respective group mean were
removed from further analyses. Student’s t-tests were performed
between control and stress groups to assess differences in gene
expression in speciﬁc brain regions. Data from Experiment 2 were
analyzed using two-way ANOVAwith Stress (control vs. stress) and
Drug (vehicle vs. NBI30775) as factors. Post hoc analyses involved
Student’s t-tests as appropriate. Signiﬁcance was set at p < 0.05.
3. Results
3.1. Peripuberty stress leads to increased Crhr1 expression in
hippocampal CA1 and central nucleus of the amygdala
Student’s t-tests revealed higher expression of Crhr1 mRNA in
the CA1 subﬁeld of the hippocampus in peripuberty stress animals
as compared to controls (Fig. 2A; t¼2.24, df¼ 14, p< 0.05), while
no signiﬁcant changes were observed in the CA3 (Fig. 2B; t¼0.55,
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p ¼ n.s.). In the amygdala, Student’s t-tests indicated no effect of
peripuberty stress on Crhr1 mRNA expression in the basolateral
amygdala (Fig. 2D; t ¼ 0.20, df ¼ 12, p ¼ n.s.), but a signiﬁcant in-
crease in the central nucleus of the amygdala (Fig. 2E; t ¼ 2.44,
df ¼ 12, p < 0.05). No difference between groups was found for
Crhr2 mRNA expression in any of the analyzed hippocampal sub-
ﬁelds or amygdala nuclei (Table S2).
3.2. Post-stress treatment with the CRHR1 antagonist affects some
behaviors in the elevated plus maze
In our previous study, peripuberty stress was found to lead to
mild, though signiﬁcant, changes in the elevated plus maze
(Marquez et al., 2013). In contrast to Marquez et al., 2013, this study
involved daily injections during the peripuberty period on both
control and stress animals, which might have affected the pro-
gramming of certain anxiety-like behaviors, as results show a
tendency in the same direction that only reaches signiﬁcance in
some parameters (Fig. 3). For example, ANOVAs of the percent time
spent by the animals in each of the relevant compartments (i.e.,
center, closed or open arms) of the apparatus reveal a lack of sig-
niﬁcant effect for each of the factors (i.e., Stress and Drug) or their
interaction for all compartments (Fig. 3A; all p > 0.5), with a ten-
dency toward signiﬁcance for the Stress factor in the percent time
spent in the center [F (1, 31) ¼ 3.21, p ¼ 0.08]. Similar results are
obtained for the distance traveled in each of the compartments
(Fig. 3B), although for the distance movedwithin the center there is
a signiﬁcant Stress  Drug interaction [F (1, 31) ¼ 5.77, p < 0.05].
Post hoc analyses revealed that Stress-Vehicle animals spent less
time in the central compartment than Control-Vehicle onesFig. 3. Effects of NBI30775 injection from postnatal P43 to P49 on anxiety-like
behavior during elevated plus maze in adulthood. (A) Percentage of time spent in
various arms (center, closed arm and open arm). (B) Distance traveled in various arms
(center, closed arm and open arm). The results are expressed as mean  SEM;
*p < 0.05; #p < 0.1; N ¼ 9 for Control-Vehicle, Control-NBI30775, PPS-NBI30775 and 8
for PPS-Vehicle.(p < 0.05), with the difference between Stress-Vehicle and Stress-
NBI30775 groups showing a tendency toward signiﬁcance
(p< 0.1). Values from Stress-NBI30775 and Control-Vehicle animals
did not signiﬁcantly differ (n.s.). No differences between groups
were found in other parameters analyzed (e.g., transitions between
zones or total distance); these data are displayed in Table S3.
3.3. Post-stress treatment with the CRHR1 antagonist reverses
social deﬁcits induced by peripuberty stress
A two-way ANOVA on total duration of juvenile exploration
(Fig. 4) revealed a signiﬁcant effect for the Stress Drug interaction
[F (1, 31)¼ 7.64, p< 0.05], but not for each of the factors, Stress [F (1,
31) ¼ 0.32, n.s.] or Drug [F (1, 31) ¼ 0.08, n.s.] separately. Post hoc
analyses reveal that the Stress-Vehicle group spent signiﬁcantly
less time exploring the juvenile than did the Control-Vehicle
(p < 0.05) or the Stress-NBI30775 (p < 0.05) groups. Control ani-
mals treated with NBI30775 show a non-signiﬁcant trend to
explore juveniles less than controls treated with vehicle (p< 0.1). A
two-way ANOVA for total duration of object exploration indicated
no effect of Stress [F (1, 32) ¼ 0.15, n.s.], Drug [F (1, 32) ¼ 0.05, n.s.]
or Stress  Drug interaction [F (1, 32) ¼ 0.58, n.s.]. Therefore, the
results of this experiment suggest that administration of NBI30775
in peripuberty stress animals during a developmental period right
after peripuberty alleviates the long-term effects of stress on
sociability.
3.4. Post-stress treatment with the CRHR1 antagonist reverses
certain alterations induced by peripuberty stress in the forced swim
test
The forced swim test included two sessions on two consecutive
days (Fig. 5). On the ﬁrst day, a two-way ANOVA on the time spent
ﬂoating revealed signiﬁcant effect of Stress Drug interaction [F (1,
32) ¼ 9.74, p < 0.05], with no effect observed for Stress [F (1,
32) ¼ 1.63, n.s.] or Drug [F (1, 32) ¼ 2.60, n.s.] separately. Post hoc
analyses revealed that all experimental groups spent more time
ﬂoating than the Control-Vehicle group (all p < 0.05). On day 2, a
two-way ANOVA revealed signiﬁcant effects of the Drug [F (1,
32)¼ 5.93, p< 0.05] and StressDrug interaction [F (1, 32)¼ 13.30,
p < 0.05], while no effect for the Stress factor [F (1, 32) ¼ 0.93, n.s.]
was observed. Post hoc analyses revealed that ﬂoating duration in
the Stress-Vehicle groups is signiﬁcantly longer than in each of the
other experimental groups (all p < 0.05). Together, these results
indicate that NBI30775 treatment stems behavioral alterationsFig. 4. Effects of NBI30775 injection from P43 to P49 on social preference test in
adulthood. The graph shows the percent time of total juvenile exploration compared to
total object exploration. The results are expressed as mean  SEM. *p < 0.05; #p < 0.1;
N ¼ 9/group.
Fig. 5. Effects of NBI30775 treatment from P43 to P49 on depression-like behavior
during forced swim test in adulthood. The graph shows the percent time of ﬂoating for
day 1 and day 2. The results are expressed as mean  SEM. *p < 0.05; N ¼ 9/group.
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forced swim test, but not on the ﬁrst. In addition, the treatment on
its own, given to non-stressed animals during the peripuberty
period leads to a differential reaction to the forced swim challenge
as compared to vehicle-treated animals on the ﬁrst exposure to the
test.
4. Discussion
Existing evidence has identiﬁed alterations in the CRH system
accompanying certain psychopathologies (Holsboer and Ising,
2008; Binder and Nemeroff, 2010) such as anxiety and depres-
sion, linked to early life adversity (Coplan et al., 1996; Nemeroff,
2004; Avital and Richter-Levin, 2005; Schmidt et al., 2007; Heim
et al., 2008; Cordero et al., 2012). Although drug treatments tack-
ling CRHR1 have been envisioned as potentially promising anxio-
lytic and antidepressive drugs (Kunzel et al., 2003; Refojo and
Holsboer, 2009), recent evidence in rodents suggests that they
could also be effective in modifying not only actual pathological
manifestations at adulthood but also the developmental trajec-
tories linking early adversity to adult psychopathology. These ro-
dent studies showed that exposure to stress during the two ﬁrst
postnatal weeks leads to increased central CRH and CRHR1
expression, and altered a number of behaviors in tests of emotion
and cognition (Plotsky et al., 2005; Ivy et al., 2010;Wang et al., 2011,
2012). Importantly, they also found that some of the long-term
behavioral alterations could be reversed by inhibiting CRHR1
function (e.g., through CRHR1 antagonist treatment or conditional
forebrain CRHR1 knockout) in the developmental period occurring
immediately after early life stress (Ivy et al., 2010; Wang et al., 2011,
2012). So far, all those studies involved maternal stress during the
ﬁrst two postnatal weeks. Here, we show that exposure of rats to
stress during the peripubertal period e comprising juvenility and
puberty e is also effective in inducing long-lasting changes in the
expression levels of the Crhr1, but not Crhr2, gene in speciﬁc hip-
pocampus and amygdala subﬁelds. Moreover, we show that treat-
ment with the CRHR1 antagonist NBI30775 daily for 1 week (from
P43eP49) immediately following peripuberty stress exposure can
also be effective in reversing certain emotional and social behaviors
observed at adulthood in peripubertally stressed animals.
We found evidence for speciﬁc increases in Crhr1 mRNA in the
CA1 hippocampal subﬁeld and in the central amygdala in adult rats
that had been subjected to peripubertal stress, but no changes in
Crhr2. These data are in alignment with other studies showing the
modulation of the CRH system in response to early life stress across
species. For example, increased cerebrospinal ﬂuid (CSF) CRH
concentrations were found in adult humans (Heim et al., 2008),non-human primates (Coplan et al., 1996) and rodents (Plotsky
et al., 2005) that had been exposed to early life adversity and
trauma. While we ﬁnd no changes in Crhr2 expression in our study,
data from previous maternal stress studies in rodents yielded
mixed results regarding changes in the central expression of this
gene (Vazquez et al., 2003; Plotsky et al., 2005; Bravo et al., 2011). In
line with our ﬁndings, increased Crhr1 mRNA expression in the
amygdala (Bravo et al., 2011) and hippocampus (Fenoglio et al.,
2006; Ivy et al., 2010; O’Malley et al., 2011) was also found in
adult rodents subjected to maternal stress during the early post-
natal period. In addition, previous evidence focused in the dorsal
raphe nucleus identiﬁed juvenility and adolescence as periods of
vulnerability for the modulation of the CRH system by stress
(Lukkes et al., 2009). Interestingly, genetic studies in humans have
pointed to an interaction between genetic variants in the Crhr1
gene and childhood maltreatment on the development of psycho-
pathological alterations (Tyrka et al., 2009; Roy et al., 2012;
Guillaume et al., 2013). Recently, a study in rhesus monkeys has
shown that single nucleotide polymorphisms in the Crhr1 gene
affect both anxiety temperament and metabolic activity in the
anterior hippocampus and amygdala (Rogers et al., 2013). Inter-
estingly, our previous data have also highlighted changes in the
metabolic activity of hippocampus and amygdala in peripubertally
stressed rats (Toledo-Rodriguez et al., 2012; Marquez et al., 2013).
Furthermore, increasing CRH drive occurring speciﬁcally in the
central amygdala through lentiviral-induced neuropeptide over-
expressionwas also found to enhance anxiety-like (Flandreau et al.,
2012) and depression-like (Keen-Rhinehart et al., 2009) behaviors
in rats. Enhanced CRHR1 expression in the hippocampus has been
linked with impaired cognitive function induced by early life stress
(Fenoglio et al., 2006; Ivy et al., 2010).
We also found that treatment with the CRHR1 antagonist
NBI30775 during the week following exposure to peripuberty
stress prevented deﬁcits in social exploration and stress-coping
behaviors displayed by peripuberty stressed animals at adult-
hood. Reduced social exploration in rodents has been related to
both depressive-like (measured as a reduction in social interest and
lack of motivation) and anxiety-like (Nestler and Hyman, 2010;
Castro et al., 2012) behaviors. Peripuberty stressed animals
showed a reduction in their exploration of the juvenile conspeciﬁc
but no difference in the exploration of the object as compared to
controls was found, and NBI30775 treatment speciﬁcally reversed
the effects of stress on social exploration. These data ﬁt with
increasing evidence implicating the CRH system in the modulation
of social behavior (Hostetler and Ryabinin, 2013). For example,
pharmacological activation of CRHR1 centrally was found to
decrease social exploration in rats (Dunn and File, 1987; Campbell
et al., 2004; Gehlert et al., 2005), an effect that was also observed
when the amygdala was directly targeted (Sajdyk et al., 1999;
Gehlert et al., 2005; Spiga et al., 2006). In agreement with our
pharmacological data, prior evidence has also shown that antago-
nizing CRHR1 has no effect on social behaviors (in our study, the
antagonist led to a non-signiﬁcant reduction in social interaction)
but is effective in abolishing the deﬁcits induced by enhanced CRH
function on sociability (Sajdyk and Gehlert, 2000; Gehlert et al.,
2005). In this context, it should be noted that CRH antagonists
have been considered promising candidates for the treatment of
social phobia in humans (van Ameringen et al., 2000).
In the forced swim test, peripuberty stressed animals showed
increased ﬂoating on the second test session, an effect classically
interpreted as evidence for increased depression-like behavior
though, following (Lu et al., 2008), we refer here to the results of
this test as stress-coping behaviors. This effect was prevented by
NBI30775 treatment. These data are in good agreement with pre-
vious reports showing that enhanced CRH drive is associated with
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view see Binder and Nemeroff, 2010) and animals (Muller and
Wurst, 2004; Kolber et al., 2010); speciﬁcally, increasing CRH
drive in the central amygdala through lentiviral-induced neuro-
peptide overexpression was found to enhance ﬂoating behaviors in
the forced swim test (Keen-Rhinehart et al., 2009). Decreasing
CRHR1 levels produces antidepressant-like effects in animals as
treatment with CRHR1 antagonists has been reported to do in
humans (Zobel et al., 2000; Kunzel et al., 2003). It is worth noting,
however, that the behavioral data obtained on the ﬁrst session of
the forced swim test depicted a slightly different picture. While
enhanced ﬂoating was again observed in peripuberty stressed an-
imals, reinforcing their impaired stress-coping behaviors and/or
depression-like phenotype, this effect was not prevented by the
NBI30775 treatment. Moreover, NBI30775 treatment on its own
also led to increased ﬂoating behavior in this ﬁrst session. Studies
involving conditional forebrain CRHR1 knockout starting around
weaning have reported effects of this manipulation at adulthood
(Zobel et al., 2000; Kunzel et al., 2003), however, most studies
administering CRHR1 antagonists to control, non-stressed animals
during early life only reported mild and non-signiﬁcant behavioral
changes (Fenoglio et al., 2005; Ivy et al., 2010). Our ﬁndings, ob-
tained at a slightly different timing of drug administration (i.e.,
post-puberty or late adolescence instead of pre-weaning regimes
given in former studies) hint at the possibility that antagonizing
CRHR1 in control individuals during adolescence might affect their
developmental trajectory and in turn affect their subsequent
emotional behavior.
Our results therefore suggest an important role of the CRHR1
system in the translation of the peripuberty effects of stress on
adult behavioral alterations and highlight the potential of CRHR1
antagonists applied in the aftermath of stress to prevent the
emergence of psychopathological behaviors. However, the data
obtained in the elevated plus maze are not conclusive as the
anxiety-like phenotype induced by peripubertal stress in the cur-
rent study is much milder than in our former reports (Marquez
et al., 2013), and only manifested as changes in the animal’s
behavior in the central compartment of the maze. No signiﬁcant
effects were observed in the time they spent in the open arms,
which is classically considered as being the index for anxiety-like
behaviors. A possible explanation for the difference in the
strength of the anxiety-like phenotype between this and our
former studies is the fact that the current study involved recurrent
injections (also in controls) during the peripuberty period which
might have affected the animals’ development in the anxiety
domain, while no injections were performed in earlier studies.
Should the anxiety-like phenotype have emerged in peripuberty
stressed animals, our prediction would have been on the effec-
tiveness of the CRHR1 antagonist treatment as an anxiolytic (see
Post et al., 2005). This hypothesis is supported by evidence showing
that the increased anxiety-like behavior displayed at adulthood in
animals subjected to early life stress was prevented in conditional
forebrain CRHR1 knockout mice in which the gene deletion takes
place from the 3rde4th postnatal week (Wang et al., 2012). It
should also be noted that although our study did not address po-
tential long-term changes in gene expression induced by the
CRHR1 antagonist treatment, previous studies with the same
antagonist have shown changes in the expression levels of Crhr1 in
the amygdala, when administered to animals under basal condi-
tions (Post et al., 2005).
In conclusion, we show enduring changes in Crhr1 expression in
the hippocampal CA1 and the central amygdala of peripuberty
stressed animals accompanying behavioral alterations in sociability
and stress-coping behaviors. We also show that these behavioral
alterations are reversed by CRHR1 antagonist treatment transientlygiven in the aftermath of stress exposure, during adolescence. Our
data highlight peripuberty as a period of plasticity for the enduring
modulation of the CRHR1 system and support a growing body of
data implicating the CRHR1 system in the programming effects of
early life stress on psychopathology, for a review, see (Regev and
Baram, 2013).
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